Clinical Trial – Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma – Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center is running a clinical trial to test a drug called Atezolizumab to treat Hodgkin Lymphoma. This is a study with the purpose of studying the safety and efficacy of the study drug Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab could shrink cancer but it could also cause side effects. This study will also test any good and bad effects the study drug. Other aims include studying biomarkers that will help researchers understand how the drug works.

The drugs is Atezolizumab.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 57 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Actual Study Start Date : April 14, 2017
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

For enrollment please visit

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.